Wellcome Leap Inc is located in Culver City, CA. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Wellcome Leap Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 09/2023, Wellcome Leap Inc generated $3.1m in total revenue. All expenses for the organization totaled $158.6m during the year ending 09/2023.
Form
990PF
Mission & Program ActivityExcerpts From the 990PF Filing
TAX YEAR
2023
Describe the Organization's Program Activity:
Part 3 - Line 4a
DELTA TISSUE: INTEGRATED PLATFORMS FOR PREDICTING CHANGES IN TISSUE STATE, IS A $55 MILLION EFFORT THAT BRINGS EXPERTS IN THE LIFE SCIENCES AND ENGINEERING TOGETHER FROM ACROSS UNIVERSITIES, FOUNDATIONS, AND THE PRIVATE SECTOR TO DEVELOP A PLATFORM THAT CAN PROFILE TISSUE STATES AND PREDICT TRANSITIONS BETWEEN STATES IN WAYS THAT ARE IMPOSSIBLE TODAY.DELTA TISSUE AIMS TO BUILD NEW PLATFORMS MULTISCALE, MULTIMODAL, AND WIDELY ACCESSIBLE THAT ALLOW US TO PREDICT HOW TISSUES WILL CHANGE IN THE FUTURE WITH THE FIDELITY NEEDED TO INTERVENE IN THE PRESENT A 'TISSUE TIME MACHINE'.
MULTI-CHANNEL PSYCH (MCPSYCH) AIMS TO DEVELOP AN INTEGRATED MODEL OF ANHEDONIC DEPRESSION THAT CAPTURES BOTH INTERNAL BIOLOGICAL FACTORS AND EXTERNALLY-MANIFESTED, QUANTIFIABLE MEASURES. THE PROGRAM ALSO SEEKS TO REVEAL BIOLOGICAL MECHANISMS OF ANHEDONIA BY SYNCHRONIZING INVESTIGATIONS ACROSS GENES, MOLECULES, CELLS, ANIMAL MODELS, AND HUMANS.MCPSYCH HAS THE GOAL OF DOUBLING THE NUMBER OF PEOPLE WHO RECEIVE AN EFFECTIVE TREATMENT ON THE FIRST TRY. IN ADDITION, THE PROGRAM SEEKS TO REVEAL MECHANISTIC UNDERSTANDING SUFFICIENT TO IDENTIFY EFFECTIVE TREATMENTS FOR HALF OF NON-RESPONSIVE PATIENTS AND HAVE THE SAME IMPACT ON THE SURVIVABILITY OF SEVERE, TREATMENT-RESISTANT DEPRESSION THAT ADVANCES IN DIAGNOSTICS AND TREATMENT HAVE HAD ON THE SURVIVABILITY OF CERTAIN CANCERS. NAMELY, THAT IN THE FUTURE, IT WILL BE POSSIBLE TO HELP 85% OF PEOPLE SURVIVE THEIR SUICIDAL ANHEDONIC DEPRESSION FOR AT LEAST 5 YEARS AND PERHAPS A FULL LIFETIME AFTER DIAGNOSIS.
THE FIRST 1000 DAYS (1KD) IS A $45 MILLION PROGRAM THAT BRINGS TOGETHER EXPERTS IN THE LIFE SCIENCES, ENGINEERING, AND COMPUTER SCIENCE FROM ACROSS UNIVERSITIES, NONPROFITS, AND THE PRIVATE SECTOR TO DEVELOP SCALABLE MEASUREMENT METHODS AND MODELS TO PREDICT AND PROMOTE HEALTHY BRAIN DEVELOPMENT IN INFANTS.THE FIRST THOUSAND DAYS CAN MAKE ALL THE DIFFERENCE TO A CHILD'S START IN LIFE, PERHAPS MORE SO THAN WE EVER UNDERSTOOD BEFORE. IN THIS EARLY PERIOD, WE DEVELOP CRITICAL COGNITIVE ABILITIES SUCH AS EXECUTIVE FUNCTION (EF) AND SELF-REGULATION. BY THE END OF THE FIRST THOUSAND DAYS, A CHILD'S INDIVIDUAL EF PERFORMANCE CHANGES THEIR ODDS OF DEALING SUCCESSFULLY WITH OPPORTUNITIES AND OBSTACLES THEY FACE IN LIFE. CHILDREN WITH UNDERDEVELOPED EF AT AGE 3 REPRESENT ABOUT 20 PERCENT OF THE POPULATION, BUT MAKE UP NEARLY 80 PERCENT OF ADULTS WHO ARE LIKELY TO REQUIRE SOME FORM OF SOCIETAL OR ECONOMIC ASSISTANCE.
THE HUMAN ORGANS, PHYSIOLOGY, AND ENGINEERING (HOPE) PROGRAM IS A $50 MILLION EFFORT THAT BRINGS EXPERTS IN THE LIFE SCIENCES AND ENGINEERING TOGETHER FROM ACROSS UNIVERSITIES, FOUNDATIONS, AND COMPANIES TO DEVELOP HUMAN TISSUES, ORGANOIDS, ORGANS, AND PLATFORMS THAT ACCELERATE AND SCALE NEW TREATMENTS.FOCUSED ON REPLICATION OF COMPLEX HUMAN ORGANS AND IMMUNE SYSTEM INTERACTIONS, IF SUCCESSFUL, THE HOPE PROGRAM WOULD HAVE ENORMOUS IMPLICATIONS FOR ADVANCING CANCER, AUTOIMMUNE, AND INFECTIOUS DISEASE INTERVENTIONS, AND, EVENTUALLY, TO BIOENGINEERED, SCALABLY-PRODUCED, IMMUNE-TOLERANT ORGANS FOR TRANSPLANTATION.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Regina Dugan Director, President & CEO | 40 | $747,620 | |
Jay Flatley Director & Chair | 1 | $150,000 | |
Michael Ferguson Director | 1 | $0 | |
Jeremy Farrar Director | 1 | $0 | |
Rachel Rogers Secretary | 40 | $208,850 | |
Kaigham Gabriel COO (through July 2023) | 40 | $605,769 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Wellcome Sanger Institute | 9/29/23 | $4,667,353 |
University Of Cambridge | 9/29/23 | $3,974,608 |
Makerere University | 9/29/23 | $3,891,957 |
King's College London | 9/29/23 | $3,535,573 |
Regents University Of California Los Angeles | 9/29/23 | $3,333,260 |
Statement of Revenue | |
---|---|
Contributions, Gifts, Grants & Similar | $2,359,904 |
Interest on Savings | $0 |
Dividends & Interest | $710,850 |
Net Rental Income | $0 |
Net Gain on Sale of Assets | $0 |
Capital Gain Net Income | $0 |
Net ST Capital Gain | $0 |
Income Modifications | $0 |
Profit on Inventory Sales | $0 |
Other Income | $4,692 |
Total Revenue | $3,075,446 |
Statement of Expenses | |
---|---|
Compensation of officers, directors, trustees, etc | $1,157,602 |
Other employee salaries and wages | $4,878,125 |
Pension plans, employee benefits | $273,093 |
Interest | $0 |
Taxes | $205,801 |
Depreciation | $144,370 |
Occupancy | $0 |
Travel, conferences, and meetings | $1,190,785 |
Printing and publications | $0 |
Other expenses | $629,373 |
Total operating and administrative expenses | $158,132,432 |
Contributions, gifts, grants paid | $480,753 |
Total expenses and disbursements | $158,613,185 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $250,100 |
Savings and temporary cash investments | $48,441,952 |
Net Accounts receivable | $0 |
Net Pledges Receivable | $278,607,708 |
Grants receivable | $0 |
Receivables from Officers, Directors, or Controlling Persons | $0 |
Net other notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $75,937,366 |
Net Investments - land, buildings, equipment | $0 |
Investments—mortgage loans | $0 |
Investments—other | $0 |
Net Land, buildings, and equipment | $74,507 |
Other assets | $86,971 |
Total assets | $403,398,604 |
Accounts payable and accrued expenses | $16,908 |
Grants payable | $0 |
Deferred revenue | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Mortgages and other notes payable | $0 |
Other liabilities | $8,034,172 |
Total liabilities | $8,051,080 |